Day 3

LEADERS FREE: Un mes de doble antiagregación parece suficiente en pacientes de alto riesgo de sangrado tratados con el stent liberados de biolimus con polímero bio absorbible.

solaci
solaci
631
0
2_philip_urban

Philip M. Urban

Previous article
TUXEDO: stent liberador de paclitaxel no alcanzó la no inferioridad en pacientes diabéticos vs el stent liberador de everolimus.
Next article
ISAR-DESIRE 4: Balón liberador de paclitaxel en reestenosis intrastent de un DES.
solaci
solaci

More articles by this author

IN.PACT SFA: Superioridad del balón farmacológico en territorio femoro poplíteo

solaci - 0
Original article John R. Laird Jr

PANDA III: stent liberador de sirolimus con polímero reabsorbible.

solaci - 0
Bo Xu

ISAR-DESIRE 4: Balón liberador de paclitaxel en reestenosis intrastent de un DES.

solaci - 0
Fundamentos: O objetivo desse estudo apresentado na sessão First Report Investigations foi comparar a eficácia anti reestenose da pré-dilatação com scoring balloon versus balão convencional...

TUXEDO: stent liberador de paclitaxel no alcanzó la no inferioridad en pacientes diabéticos vs el stent liberador de everolimus.

solaci - 0
Upendra Kaul

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Aneurysm Sac Regression Predicts Better Clinical Outcomes After EVAR?

Dr. Juan Manuel Pérez - 0
Aneurysm sac regression following endovascular abdominal aortic aneurysm repair (EVAR) has been proposed as a marker of favorable remodeling and effective aneurysm exclusion. However,...

Inflammation after TAVI: An Emerging Therapeutic Target?

Dr. Juan Manuel Pérez - 0
Conduction disturbances and the need for permanent pacemaker implantation remain common complications following TAVI, with an incidence approaching 15%. Although they have traditionally been...

SPYRAL Program: 3-Year Outcomes in Patients Treated with Renal Denervation

Dr. Andrés Rodríguez - 0
Hypertension is the leading modifiable risk factor for cardiovascular disease and remains a major global health challenge, affecting more than one billion adults worldwide.  Despite...